Therapy for mycosis fungoides

Current Treatment Options in Oncology

Volumn 5, Issue 3, 2004, Pages 203-214

  Lundin, Jeanette ^a   Österborg, Anders ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEXAROTENE; CARMUSTINE; CHIMERIC ANTIBODY; CHLORAMBUCIL; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; INTERLEUKIN 2; METHOTREXATE; METHOXSALEN; MONOCLONAL ANTIBODY; OKT 4; PEGINTERFERON; PENTOSTATIN; PHOTOSENSITIZING AGENT; PREDNISONE; PSORALEN; RETINOID; TUMOR VACCINE; UNINDEXED DRUG; VINCRISTINE;

ADVANCED CANCER; ANEMIA; BACKACHE; BLOOD TOXICITY; BULLOUS SKIN DISEASE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG RESPONSE; DYSPNEA; ELECTRON BEAM; ERYTHEMA; EXFOLIATIVE DERMATITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTOXICITY; GRANULOCYTOPENIA; HEADACHE; HEMATURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOTENSION; HYPOTHYROIDISM; INFECTION; INSOMNIA; LEUKOCYTOCLASTIC VASCULITIS; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE DISEASE; OPPORTUNISTIC INFECTION; PAIN; PROGNOSIS; PRURITUS; PURPURA; PUVA; REVIEW; SKIN ATROPHY; STEM CELL TRANSPLANTATION; SYMPTOMATOLOGY; THORAX PAIN; TREATMENT INDICATION; VOMITING; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHOTOTHERAPY; SKIN TUMOR;

COMBINED MODALITY THERAPY; FICUSIN; HUMANS; INTERFERON-ALPHA; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS; ULTRAVIOLET THERAPY;

EID: 4444311807     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0012-8     Document Type: Review

References (50)

1. Smoller BR, Bishop K, Glusac E, et al.: Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol 1995, 19: 1423-1430.
2. Tensen CP, Flier J, Van Der Raaij-Helmer EM, et al.: Human IP-9: a keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol 1999, 112: 716-722.
3. Kakinuma T, Sugaya M, Nakamura K, et al.: Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003, 48: 23-30.
4. Rook A, Heald P: The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9: 997-1010.
5. DeVita V, Hellman S, Rosenberg SA: Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2001.
6. Bunn PA Jr, Lamberg SI: Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979, 63: 725-728.
7. van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000, 136: 504-510.
8. Zackheim HS: Treatment of mycosis fungoides/Sezary syndrome: the University of California, San Francisco (UCSF) approach. Int J Dermatol 2003, 42: 53-56.
9. Esteve E, Bagot M, Joly P, et al.: A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas. Arch Dermatol 1999, 135: 1349-1353.
10. Foulc P, Evrard V, Dalac S, et al.: Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment. Br J Dermatol 2002, 147: 926-930.
11. Liu HL, Kim YH: Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 2002, 138: 398-399.
12. Heald P, Mehlmauer M, Martin AG, et al.: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 2003, 49: 801-815.
13. Herrmann JJ, Roenigk HH Jr, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995, 33: 234-242.
14. Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med 1987, 316: 297-303.
15. Fritz TM, Kleinhans M, Nestle FO, et al.: Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sezary syndrome. Br J Dermatol 1999, 140: 1144-1147.
16. Micaily B, Miyamoto C, Kantor G, et al.: Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 1998, 42: 361-364.
17. Hoppe RT, Cox RS, Fuks Z, et al.: Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep 1979, 63: 691-700.
18. Wilson LD, Licata AL, Braverman IM, et al.: Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 1995, 32: 987-995.
19. Wilson LD, Jones GW, Kim D, et al.: Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000, 43: 54-60.
20. Jones GW, Kacinski BM, Wilson LD, et al.: Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002, 47: 364-370.
21. Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9: 1089-1107.
22. Stadler R, Otte HG, Luger T, et al.: Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998, 92: 3578-3581.
23. Winkelmann RK, Diaz-Perez JL, Buechner SA: The treatment of Sezary syndrome. J Am Acad Dermatol 1984, 10: 1000-1004.
24. Zackheim HS, Kashani-Sabet M, Hwang ST: Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996, 34: 626-631.
25. Akpek G, Koh HK, Bogen S, et al.: Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999, 86: 1368-1376.
26. Muche JM, Gellrich S, Sterry W: Treatment of cutaneous T-cell lymphomas. Semin Cutan Med Surg 2000, 19: 142-148.
27. Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2000, 42: 40-46.
28. Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003, 98: 993-1001.
29. Ho AD, Suciu S, Stryckmans P, et al.: Pentostatin in T-cell malignancies: a phase II trial of the EORTC. Leukemia Cooperative Group. Ann Oncol 1999, 10: 1493-1498.
30. Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999, 17: 3117-3121.
31. Scarisbrick JJ, Child FJ, Clift A, et al.: A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 2001, 144: 1010-1015.
32. Zinzani PL, Baliva C, Magagnoli M, et al.: Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000, 18: 2603-2606.
33. Sallah S, Wan JY, Nguyen NP: Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001, 113: 185-187.
34. Zhang C, Hazarika P, Ni X, et al.: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002, 8: 1234-1240.
35. Duvic M, Martin AG, Kim Y, et al.: Phase II and III clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001, 137: 581-593.
36. Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II/III trial results. J Clin Oncol 2001, 19: 2456-2471.
37. Talpur R, Ward S, Apisamthanarax N, et al.: Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002, 47: 672-684.
38. Lundin J, Hagberg H, Repp R, et al.: Phase II study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003, 101: 4267-4272.
39. Kennedy GA, Seymour JF, Wolf M, et al.: Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 2003, 71: 250-256.
40. Knox S, Hoppe RT, Maloney D, et al.: Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996, 87: 893-899.
41. Obitz E, Kim H, Iversen L, et al.: HuMaX-CD4, A fully human monoclonal antibody: early results of an ongoing phase II trial in cutaneous T-cell lymphoma (CTCL) [abstract]. Blood 2003, 102: 645a
42. Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001, 19: 376-388.
43. Foss FM, Bacha P, Osann KE, et al.: Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001, 1: 298-302.
44. Donato M, Kurzrock R, Champlin R, et al.: Complete remission at late-stage mycosis fungoides/Sezary syndrome following allogeneic transplantation. Blood 2003, 102: 731a.
45. Molina A, Zain J, Arber D, et al.: Is allogeneic hematopoietic stem cell transplantation (AHSCT) potentially curative in a group of refractory cutaneous T-cell lymphomas (CTCLs)? Durable clinical, cytogenetic and molecular remissions after AHSCT for refractory Sezary syndrome and mycosis fungoides. Blood 2003, 102: 476a.
46. Kaplan EH, Rosen ST, Norris DB, et al.: Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990, 82: 208-212.
47. Duvic M, Talpur R, Chiao N, Chiao J: Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Blood 2003, 102: 179a.
48. Rook AH, Wood GS, Yoo EK, et al.: Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999, 94: 902-908.
49. Rook AH, Zaki MH, Wysocka M, et al.: The role for interleukin-12 therapy of cutaneous T-cell lymphoma. Ann N Y Acad Sci 2001, 941: 177-184.
50. Maier T, Tun-Kyi A, Tassis A, et al.: Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 2003, 102: 2338-2344.